Recurrent Squamous Cell Lung Carcinoma Recruiting Phase 2 Trials for Durvalumab (DB11714)

IndicationStatusPhase
DBCOND0044226 (Recurrent Squamous Cell Lung Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03373760Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerTreatment